Castle Creek Biosciences is focused on developing commercializing novel, personalized gene therapies for rare skin disorders.
Castle Creek Biosciences has raised $75.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in February 2025.
Castle Creek Biosciences's investors include Valor Equity Partners, Fidelity, Ligand Pharmaceuticals, Horizon Technology Finance, Paragon Biosciences.
Castle Creek Biosciences is headquartered in Exton, United States.
Castle Creek Biosciences is focused on developing commercializing novel, personalized gene therapies for rare skin disorders.
Castle Creek Biosciences is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Castle Creek Biosciences — Funding & Investors." VCBacked, February 25, 2025, https://www.vcbacked.co/company/castle-creek-biosciences. Accessed August 14, 2026.
VCBacked. (2025). Castle Creek Biosciences — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/castle-creek-biosciences
{{cite web |title=Castle Creek Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/castle-creek-biosciences |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated